iSpecimen Receives Nasdaq Notice for Noncompliance with Minimum Bid Price

Reuters11-22
iSpecimen Receives Nasdaq Notice for Noncompliance with Minimum Bid Price

iSpecimen Inc. announced that it has received a notice from the Nasdaq Stock Market indicating that the company is not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. The company's stock has traded below this threshold for 30 consecutive business days. iSpecimen has 180 calendar days, until May 18, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. The company may be eligible for an additional 180-day compliance period if it meets other listing standards. iSpecimen's stock will continue to trade under the symbol "ISPC" as the company evaluates its options to address the deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iSpecimen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-113708), on November 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment